2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary

dc.contributor.author
Losa, F.
dc.contributor.author
Iglesias, L.
dc.contributor.author
Pané, M.
dc.contributor.author
Sanz, J.
dc.contributor.author
Nieto, B.
dc.contributor.author
Fusté, V.
dc.contributor.author
de la Cruz‑Merino, L.
dc.contributor.author
Concha, Ángel
dc.contributor.author
Balañá, Carme
dc.contributor.author
Matias-Guiu, Xavier
dc.date.accessioned
2024-12-05T22:14:19Z
dc.date.available
2024-12-05T22:14:19Z
dc.date.issued
2021-03-22T09:28:42Z
dc.date.issued
2021-03-22T09:28:42Z
dc.date.issued
2018
dc.identifier
https://doi.org/10.1007/s12094-018-1899-z
dc.identifier
1699-3055
dc.identifier
http://hdl.handle.net/10459.1/70821
dc.identifier.uri
http://hdl.handle.net/10459.1/70821
dc.description.abstract
Cancer of unknown primary (CUP) is defned as a heterogeneous group of tumours that present with metastasis, and in which attempts to identify the original site have failed. They difer from other primary tumours in their biological features and how they spread, which means that they can be considered a separate entity. There are several hypotheses regarding their origin, but the most plausible explanation for their aggressiveness and chemoresistance seems to involve chromosomal instability. Depending on the type of study done, CUP can account for 2–9% of all cancer patients, mostly 60–75 years old. This article reviews the main clinical, pathological, and molecular studies conducted to analyse and determine the origin of CUP.The main strategies for patient management and treatment, by both clinicians and pathologists, are also addressed.
dc.description.abstract
The authors are grateful for the editorial assistance of Dr. Fernando Sánchez-Barbero of HealthCo (Madrid, Spain) in the production of this manuscript. SEOM and SEAP are grateful for the fnancial support for this project in the form of unrestricted grants from Ferrer Diagnostic, OncoDNA and Foundation Medicine/Roche.
dc.language
eng
dc.publisher
Springer
dc.relation
Reproducció del document publicat a https://doi.org/10.1007/s12094-018-1899-z
dc.relation
Clinical & Translational Oncology, 2018, vol. 20, núm. 11, p.1361-1372
dc.rights
cc-by (c) Losa et al., 2018
dc.rights
info:eu-repo/semantics/openAccess
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.subject
Cancer of unknown primary
dc.subject
Diagnosis
dc.subject
Immunohistochemistry
dc.subject
Biopsy
dc.subject
Prognosis
dc.subject
Chemotherapy
dc.subject
Molecular pathology
dc.subject
Histopathology
dc.title
2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)